clofibric acid has been researched along with Hyperlipoproteinemia Type II in 42 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clofibrate was administered to 5 selected outpatients suffering from type IIa hyperlipoproteinaemia who had previously undergone dietetic treatment, and one female patient suffering from hypo-HDL-aemia in order to elucidate the question as to whether medium long term clofibrate therapy apart from producing an initial increase relative to the LDL concentration may also lead to an absolute increase in the concentration of HDL cholesterol in serum." | 5.26 | [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. ( Mertz, DP, 1980) |
| "Simvastatin was associated with statistically significantly greater (p < or = 0." | 2.68 | Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia. ( Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W, 1995) |
| " Safety was assessed from reports of adverse events and by measuring haematological and biochemical parameters." | 2.68 | Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia. ( Betteridge, DJ; O'Bryan-Tear, CG, 1996) |
| "Ciprofibrate has the benefit of a long half-life and may also be administered in the form of a single daily dose to patients suffering from major type II hyperlipoproteinaemia." | 2.66 | Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B. ( Bakir, R; Chanu, B; Djian, F; Goy-Loeper, J; Rouffy, J, 1985) |
| "Ciprofibrate was convenient to take and was without subjective side effects." | 1.26 | Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia. ( Olsson, AG; Orö, L, 1982) |
| "Treatment with clofibric acid over a long period of time may well give rise to additional reactions through influences exerted upon the insulin level." | 1.26 | [Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life]. ( Reuter, W, 1982) |
| "One patient with familial hypercholesterolemia (untreated total cholesterol 800 mg%) received a combined drug treatment during 5 years." | 1.26 | Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs. ( Ditschuneit, H; Hutt, V; Klör, HU; Wechsler, JG, 1980) |
| "Bezafibrate is a potent lipid-lowering agent of the new generation." | 1.26 | Clinical experience with bezafibrate. ( Hausmann, L; Kaffarnik, H; Mühlfellner, G; Mühlfellner, O; Schneider, J; Schubotz, R, 1980) |
| "Clofibrate was administered to 5 selected outpatients suffering from type IIa hyperlipoproteinaemia who had previously undergone dietetic treatment, and one female patient suffering from hypo-HDL-aemia in order to elucidate the question as to whether medium long term clofibrate therapy apart from producing an initial increase relative to the LDL concentration may also lead to an absolute increase in the concentration of HDL cholesterol in serum." | 1.26 | [Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate]. ( Mertz, DP, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 33 (78.57) | 18.7374 |
| 1990's | 5 (11.90) | 18.2507 |
| 2000's | 4 (9.52) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaye, T | 1 |
| Guerin, M | 1 |
| Le Goff, W | 1 |
| Frisdal, E | 1 |
| Schneider, S | 1 |
| Milosavljevic, D | 1 |
| Bruckert, E | 2 |
| Chapman, MJ | 1 |
| Kourimate, S | 1 |
| Le May, C | 1 |
| Langhi, C | 1 |
| Jarnoux, AL | 1 |
| Ouguerram, K | 1 |
| Zaïr, Y | 1 |
| Nguyen, P | 1 |
| Krempf, M | 1 |
| Cariou, B | 1 |
| Costet, P | 1 |
| Kaffarnik, H | 2 |
| Schneider, J | 2 |
| Schubotz, R | 2 |
| Zöfel, P | 1 |
| Hausmann, L | 2 |
| Goebel, KM | 1 |
| Stewart, JM | 1 |
| Packard, CJ | 1 |
| Lorimer, AR | 1 |
| Boag, DE | 1 |
| Shepherd, J | 1 |
| Paoletti, R | 1 |
| Franceschini, G | 1 |
| Sirtori, CR | 1 |
| Soler, J | 2 |
| Vinzia, C | 1 |
| Gómez, JM | 1 |
| Morató, J | 1 |
| Illingworth, DR | 1 |
| Olsen, GD | 1 |
| Cook, SF | 1 |
| Sexton, GJ | 1 |
| Wendel, HA | 1 |
| Connor, WE | 1 |
| Reuter, W | 2 |
| Neuman, MP | 1 |
| Kurlat, MI | 1 |
| Neuman, J | 1 |
| Olsson, AG | 1 |
| Orö, L | 1 |
| Altomonte, L | 2 |
| Mingrone, G | 2 |
| Negrini, A | 1 |
| De Cunto, F | 1 |
| Greco, AV | 2 |
| Kokot, F | 1 |
| Szczechowska, E | 1 |
| Bonora, V | 1 |
| Calalabuig, RJ | 1 |
| Caviola, E | 1 |
| Pueyo, JM | 1 |
| Micaló, T | 1 |
| Cano, RP | 1 |
| Schwartzkopff, W | 2 |
| Luley, C | 2 |
| Scheffler, W | 2 |
| Lehmann-Leo, W | 1 |
| Schilling, A | 2 |
| Wegscheider, K | 1 |
| Vessby, B | 1 |
| Lithell, H | 1 |
| Ledermann, H | 1 |
| Udelhoven, P | 1 |
| Wirth, A | 1 |
| Middelhoff, G | 1 |
| Braeuning, C | 1 |
| Schlierf, G | 2 |
| Wechsler, JG | 2 |
| Hutt, V | 2 |
| Klör, HU | 2 |
| Ditschuneit, H | 2 |
| Mühlfellner, G | 1 |
| Mühlfellner, O | 1 |
| Lopez Rodriguez, J | 1 |
| Martorell, J | 1 |
| Ghirlanda, G | 1 |
| Manna, R | 1 |
| Rebuzzi, A | 1 |
| Pala, MA | 1 |
| Noseda, G | 1 |
| Fragiacomo, C | 1 |
| Weidmann, P | 1 |
| Bachmann, C | 1 |
| Calder, D | 1 |
| Domingo, AJ | 1 |
| Gutiérrez, JA | 1 |
| Menéndez, JA | 1 |
| Micó, L | 1 |
| Muñoz, M | 1 |
| de Oya, M | 1 |
| Mertz, DP | 2 |
| Freyberger, H | 1 |
| Schifferdecker, E | 1 |
| Schatz, H | 1 |
| Virgolini, I | 1 |
| Koller, E | 1 |
| Li, S | 1 |
| Yang, Q | 1 |
| Banyai, M | 1 |
| Rauscha, F | 1 |
| Pidlich, J | 1 |
| Pirker, W | 1 |
| Sinzinger, H | 1 |
| De Gennes, JL | 1 |
| Malbecq, W | 1 |
| Baigts, F | 1 |
| Betteridge, DJ | 1 |
| O'Bryan-Tear, CG | 1 |
| Kockx, M | 1 |
| de Maat, MP | 1 |
| Knipscheer, HC | 1 |
| Kastelein, JJ | 1 |
| Kluft, C | 1 |
| Princen, HM | 1 |
| Kooistra, T | 1 |
| Okopien, B | 1 |
| Cwalina, L | 1 |
| Lebek, M | 1 |
| Kowalski, J | 1 |
| Zielinski, M | 1 |
| Wisniewska-Wanat, M | 1 |
| Kalina, Z | 1 |
| Herman, ZS | 1 |
| Gustafson, A | 1 |
| Loewer, H | 1 |
| Suermann, I | 1 |
| Bolzano, K | 1 |
| Krempler, F | 1 |
| Schellenberg, B | 1 |
| Hunninghake, DB | 1 |
| Peters, JR | 1 |
| Palmer, RH | 1 |
| Rodriguez, F | 1 |
| López, IM | 1 |
| Jover, E | 1 |
| Jacotot, B | 1 |
| Beaumont, JL | 1 |
| Beaumont, V | 1 |
| Buxtorf, JC | 1 |
| Edouard, L | 1 |
| Doucet, F | 1 |
| Carcone, B | 1 |
| Rouffy, J | 1 |
| Chanu, B | 1 |
| Bakir, R | 1 |
| Djian, F | 1 |
| Goy-Loeper, J | 1 |
2 reviews available for clofibric acid and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
Topics: Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Fenofibrate; Fibric Acids; Gemfib | 1987 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
15 trials available for clofibric acid and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Action of ciprofibrate in type IIb hyperlipoproteinemia: modulation of the atherogenic lipoprotein phenotype and stimulation of high-density lipoprotein-mediated cellular cholesterol efflux.
Topics: Adult; Animals; Apolipoprotein A-I; Apolipoproteins B; Arteriosclerosis; Cholesterol; Cholesterol Es | 2003 |
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins | 1983 |
Ciprofibrate in the therapy of type II hypercholesterolemia. A double-blind trial.
Topics: Adult; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Fibric Aci | 1982 |
[Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
Topics: Adult; Aged; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Huma | 1981 |
[Comparison of the lipid-lowering agents clofibrate and bezafibrate in patients with hyperlipoproteinemias IIa and IIb].
Topics: Adult; Bezafibrate; Cholesterol; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind | 1981 |
Treatment of hyperlipoproteinemia, types II and IV, with pirifibrate: one hundred observations.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Clofibric Acid; Humans; Hyperlipoproteinemia Type | 1981 |
[Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Clofibrate; Clofibric Acid; Female; Fenofibrate; | 1982 |
Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
Topics: Adult; Apolipoproteins; Bezafibrate; Body Weight; Cholesterol; Cholesterol, LDL; Clofibrate; Clofibr | 1982 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Fema | 1995 |
Comparative efficacy and safety of ciprofibrate and sustained-release bezafibrate in patients with type II hyperlipidaemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Delayed-A | 1996 |
Effects of gemfibrozil and ciprofibrate on plasma levels of tissue-type plasminogen activator, plasminogen activator inhibitor-1 and fibrinogen in hyperlipidaemic patients.
Topics: Adult; Aged; Cholesterol; Clofibric Acid; Double-Blind Method; Female; Fibric Acids; Fibrinogen; Gem | 1997 |
Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Fibrin | 2001 |
Effects of fibric acid derivatives on biliary lipid composition.
Topics: Bezafibrate; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Double-Blind Method; Female; Feno | 1987 |
Effects of several lipid-lowering drugs on skin total and esterified cholesterol.
Topics: Cholesterol Esters; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibric Acids; Humans; Hyp | 1986 |
Comparative evaluation of the effects of ciprofibrate and fenofibrate on lipids, lipoproteins and apoproteins A and B.
Topics: Adult; Apolipoproteins A; Apolipoproteins B; Clofibrate; Clofibric Acid; Drug Evaluation; Female; Fe | 1985 |
26 other studies available for clofibric acid and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Simvastatin with or without ezetimibe in familial hypercholesterolemia.
Topics: Anticholesteremic Agents; Azetidines; Clofibric Acid; Drug Therapy, Combination; Ezetimibe; Humans; | 2008 |
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Topics: Anticholesteremic Agents; Cell Line, Tumor; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Furin | 2008 |
Long-term treatment of hyperlipoproteinemia with etofibrate: clinical observations.
Topics: Adult; Aged; Cholesterol; Clofibrate; Clofibric Acid; Creatine Kinase; Female; gamma-Glutamyltransfe | 1980 |
Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinaemic subjects.
Topics: Adult; Apolipoproteins; Apolipoproteins B; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, | 1982 |
[Plafibride treatment of hyperlipidemias type II and IV].
Topics: Adult; Cholesterol; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperl | 1984 |
[Effect of combination therapy of clofibric acid and nicotinic acid derivatives on fatty acid metabolism in hyperlipoproteinemia].
Topics: Aged; Clofibrate; Clofibric Acid; Drug Therapy, Combination; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Elevation of high density lipoprotein cholesterol (cHDL) and reduction of the total cholesterol/cHDL index in the treatment of hyperlipoproteinaemias IIb and IV with bezafibrate.
Topics: Adult; Aged; Bezafibrate; Cholesterol; Cholesterol, HDL; Clofibrate; Clofibric Acid; Female; Humans; | 1983 |
Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.
Topics: Alanine Transaminase; Aspartate Aminotransferases; Blood Sedimentation; Body Weight; Cholesterol; Ch | 1982 |
Elevated lipoprotein lipase activity in skeletal muscle tissue during treatment of hypertriglyceridaemic patients with bezafibrate.
Topics: Adipose Tissue; Adult; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia | 1982 |
[Lipid lowering improved? Therapeutic progress by using biological mechanisms].
Topics: Anticholesteremic Agents; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II | 1982 |
[Effect of clofibric acid on fatty acid metabolism in HLP patients in the 2d half of life].
Topics: Adult; Aged; Cholesterol Esters; Clofibrate; Clofibric Acid; Fatty Acids; Female; Humans; Hyperlipop | 1982 |
Lipids and lipoproteins in hyperlipidemia type IIa during treatment with different lipid lowering drugs.
Topics: Adolescent; Bezafibrate; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; I | 1980 |
Clinical experience with bezafibrate.
Topics: Bezafibrate; Blood Glucose; Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Coronary Disease; | 1980 |
Pirifibrate in the treatment of hyperlipoproteinemia: types IIa, IIb, and IV.
Topics: Adolescent; Adult; Aged; Cholesterol; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
[Bile lipid composition in subjects with blood lipid disorders (types II and IV). Effect of a new hypolipemic drug (Etofibrate)].
Topics: Adult; Aged; Bile; Clofibrate; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperli | 1980 |
[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types].
Topics: Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipoproteinemia Type II; Hyperlip | 1980 |
Changes in lipids and lipoproteins in patients with hyperlipidemia type IIb, IV and V treated with different lipid lowering drugs.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Humans; Hyperlipopro | 1980 |
The effect of etofibrate retard, bezafibrate and procetofen.
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Female; Fenofibrate; Humans; Hyperlipopr | 1980 |
Pirifibrate in the treatment of hyperlipoproteinemias: a multicenter study.
Topics: Adult; Aged; Clofibric Acid; Female; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type | 1980 |
[Clofibrate therapy in hypercholesterolemia. Reports on medium-long-term movements of HDL- cholesterol by the action of clofibrate].
Topics: Adult; Bezafibrate; Clofibrate; Clofibric Acid; Drug Administration Schedule; Female; Humans; Hyperc | 1980 |
[Regression of hard exudates in diabetic background retinopathy in therapy with etofibrate antilipemic agent].
Topics: Adult; Blood Glucose; Clofibric Acid; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Female; Fundu | 1994 |
Etofibrate increases binding of low and high density lipoprotein to human platelets of patients with type II hyperlipoproteinemia.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins B; Blood Platelets; Cholesterol; Cholesterol, HDL; | 1993 |
Treatment of hyperlipoproteinemia type II with etofibrate.
Topics: Body Weight; Cholesterol; Clofibrate; Clofibric Acid; Glucose Tolerance Test; Humans; Hyperlipoprote | 1979 |
[The range and lipid-lowering effect of etofibrate as a retard-preparation in patients with hyperlipoproteinemia type IIa (author's transl)].
Topics: Adult; Aged; Anticholesteremic Agents; Clofibrate; Clofibric Acid; Delayed-Action Preparations; Fema | 1979 |
[A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
Topics: Adult; Aged; Bezafibrate; Clofibrate; Clofibric Acid; Dose-Response Relationship, Drug; Female; Huma | 1979 |
Plafibride treatment and serum lipids in hyperlipoproteinemias.
Topics: Adolescent; Adult; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diet; Female; Humans; Hyp | 1987 |